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ABSTRACT 
Evaluating the Potential Antihyperalgesic Effects of Curcumin on a Laboratory Model of 
Neuropathic Pain. (May 2014) 
 
Carli Marie Domenico 
Department of University Studies: Honors 
Texas A&M University 
 
Research Advisor: Dr. Mary Meagher 
Department of Psychology  
 
Curcumin is an anti-inflammatory and anti-oxidative, herbal supplement that has been utilized in 
the animal model to evaluate its potential for anti-inflammatory and anti-nociceptive effects 
among other benefits. This ongoing pilot study examined whether humans show a similar pattern 
of benefits after acute consumption of curcumin supplements for seven days. Participants 
underwent two laboratory visits in which capsaicin-induced spontaneous pain, neurogenic 
inflammation, primary and secondary hyperalgesia, and heat-pain detection thresholds were 
measured at baseline and post-treatment. Topical capsaicin mimics neuropathic pain by 
sensitizing the peripheral and central pain pathway. We hypothesized that curcumin would have 
anti-inflammatory and anti-hyperalgesic effects that would inhibit the neurogenic inflammatory 
flare response while also inducing an anti-hyperalgesic effect indicated by reduced ratings of 
spontaneous pain and stimulus-evoked primary and secondary hyperalgesia. Results have shown 
a decrease in suprathreshold pain intensity and unpleasantness ratings as well as capsaicin-
induced spontaneous pain intensity and unpleasantness ratings. Furthermore, results suggest a 
marked increase in valence during pain testing during the second visit in addition to increased 
dominance ratings and decreased arousal. Preliminary results show that curcumin may be an 
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effective anti-hyperalgesic supplement in a healthy undergraduate population. Ongoing tests will 
give further insight into curcumin’s potential on impacting pain processes.  
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NOMENCLATURE 
SAM     Self Assessment Manikin 
VAS     Visual Analog Scale 
C-ESD     Center for Epidemiologic Studies Depression Scale 
DASS     Depression Anxiety Stress Scale 
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CHAPTER I 
INTRODUCTION 
 
In 2010, a survey-based study deduced that chronic pain plagues 30.7% of the United States 
population, and a majority of those experiencing chronic pain are of lower socioeconomic status 
and thus less financially prepared to treat their condition (Johannes et al., 2010). Furthermore, 
since chronic pain is one of the most common reasons for medical visits, solutions are needed to 
alleviate this common problem as current treatments are not sufficient to manage a condition as 
complex as pain (Gureje et al., 1998). The healthcare cost attributed to pain in 2010 was between 
261 and 300 billion dollars with an additional loss of 229 to 335 billion dollars in costs from lost 
productivity due to pain (Gaskin and Richard, 2012). This cost is greater than that of heart 
disease, cancer, or diabetes, and it does not even account for “nursing home residents, children, 
military personnel, or persons who are incarcerated” (Gaskin and Richard, 2012).  Recent 
research has found that Curcumin, also known as turmeric, an herb used in food spices and 
herbal medicine, has therapeutic effects due to its anti-inflammatory properties (Arora et al., 
1997; Kandhare et al., 2012; Singh, 2007).  The anti-inflammatory and antioxidant effects of 
curcumin may be responsible for its medicinal use against chronic diseases that involve 
neurodegenerative, cardiovascular, and metabolic diseases (Sandur et al, 2007).  Oxidative stress 
plays a role in the causation of chronic pain, and antioxidants like curcumin reverse these effects 
by assisting in the elimination of free radicals (Kandhare et al., 2012). Recent studies in animals 
have shown that curcumin is antihyperalgesic and attenuates levels of inflammatory cytokines, 
which determine the initiation, severity, and maintenance of pain as well as the inflammation 
response observed in injured tissue (Kandhare et al., 2012; Yeon et al., 2010). Animal studies 
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have shown that curcumin attenuates thermal hyperalgesia (the experience of increased 
sensitivity from a noxious thermal stimulus), mechanical allodynia (pain from an innocuous 
mechanical stimulus), and capsaicin induced hyperalgesia (Kandhare et al. 2012; Mittal et al, 
2009; Tajik et al., 2008; Yeon et al., 2010; Zhao et al., 2011). To our knowledge, this is the first 
study performed on humans looking at the effects of curcumin on neurogenic inflammation and 
hyperalgesia. This study will give insights into the effects of curcumin on human pain processes 
and will serve as a pilot study for further research into its therapeutic effects on chronic pain.  
 
This study’s goal is to determine whether curcumin alters measures of peripheral and central 
sensitization of pain in a human model by comparing differences in the flare response 
(neurogenic inflammation), thermal pain threshold, suprathreshold pain, capsaicin-induced 
primary and secondary hyperalgesia, and perception of pain intensity between those taking 
curcumin and those taking placebo. Primary hyperalgesia involves the experience of increased 
sensitivity to a noxious stimulus at the site of application, and secondary hyperalgesia involves 
this experience in tissue surrounding the application site. We hypothesize that participants will 
have significantly reduced flare and hyperalgesia responses to capsaicin after curcumin intake 
compared to participants with placebo after seven days.  
 
Curcumin has shown anti-inflammatory and antioxidant effects that may act to decrease 
neurogenic inflammation and its role in the sensitization of pain. Mounting evidence suggests 
that curcumin may reduce inflammation and pain by downregulating proinflammatory cytokines’ 
expression, which normally play a major role in the sensitization of pain. Prior research indicates 
that curcumin downregulates the production of these inflammatory cytokines, chemokines, and 
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prostaglandins, including interleukin-1 (IL-1), IL-6, Tumor Necrosis Factor-alpha (TNF-alpha), 
IL-8, MIP-1alpha, NCP-1, and Cox-2 by blocking the activation of the nuclear factor kappa B 
(NF-κB) transcription pathway. The NF-κB pathway is a key regulator of proinflammatory 
cytokine release (Aggarwal & Harikumar, 2009). Previous studies indicate that inflammatory 
cytokines enhance neurogenic flare, the perception of pain, and the area of secondary 
hyperalgesia, a measure of chronic pain (Kandhare et al., 2012; Sharma, 2006). 
 
 In addition to affecting pain through inflammation and oxidants, the structure of curcumin has 
been shown to inhibit thermal hyperalgesia induced by capsaicin, most likely due to the vanilloid 
structure shared by capsaicin and curcumin that helps curcumin block the TRPV1 receptor 
(Gupta et al., 2012; Yeon et al., 2010). Furthermore curcumin inhibits NF-κB transcription of 
cytokines (Aggarwal & Harikumar, 2009). The current study is designed to further research on 
curcumin and its therapeutic effects as previous studies involving this herbal supplement have 
not yet looked at peripheral and central sensitization of pain in a human laboratory model. 
Peripheral and central sensitization of pain involve an alteration of the properties of neurons in 
the central nervous system, which results in a change in synaptic efficacy causing enhanced pain 
sensitivity. Importantly, these processes are known to contribute to the induction and 
maintenance of chronic pain. Peripheral sensitization occurs only at the site of injury and is 
caused by inflammation, which reduces nociceptor thresholds. The present experiment aims to 
determine whether the previous anti-inflammatory and anti-hyperalgesic effects of curcumin 
observed in animal pain studies will translate to humans. Thus, if curcumin reduces capsaicin-
induced laboratory pain using the same methods and measures of chronic pain processes as used 
in prior animal studies, it may provide a safe and affordable means to prevent or mitigate the 
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inflammation and hyperalgesia associated with chronic pain conditions such as fibromyalgia or 
arthritis. 
 
Curcumin is inexpensive, safe in high doses even at 12 grams a day in humans, and is declared as 
“generally regarded as safe (GRAS)” by the United States FDA (Cheng et al., 2001; Lao et al., 
2006; Moreaux et al., 2004).  Many clinical trials have involved curcumin and its effect on 
chronic diseases, and the majority of studies have observed biological responses and symptom 
reduction (Aggarwal & Sung, 2009; Goel A. Kunnumakkara AB, 2007). This study will compare 
the effects of curcumin on various properties of pain based on acute consumption of either 
curcumin or placebo for seven days. 
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CHAPTER II 
METHODS AND MATERIALS 
 
All procedures were approved by the IRB at Texas A&M University, and informed consent was 
obtained from all participants. As participants received course credits for their participation, they 
were informed that they could withdraw from the study at any time without forfeiting the credit, 
and they could instead do extra credit as described in their course syllabus. Data obtained from 
the subjects were de- identified so only number identified the participants, not name or initials.  
 
2.1 Participants  
Undergraduates at Texas A&M University enrolled in Psychology 107 were prescreened to 
determine eligibility to enroll in the study. Participants of 18 years of age and older who met 
inclusion criteria were sent an invitation email to participate in the study. The exclusionary 
criteria included current use of psychoactive drugs, history of vasovagal syncope (fainting), 
chronic illness, allergy to chili pepper, a skin condition or injury on the forearm, alcohol or drug 
abuse, use of steroids, ACE-inhibitors, blood thinners, antihistamines, and mood altering 
medications. Furthermore, participants could not be a smoker, pregnant, nursing, vegetarian, or 
diabetic. They could not have a BMI of 30 or higher, indicating obesity, consume fish oil, 
flaxseed, turmeric, or capsaicin regularly, or eat more than two portions of oily fish per week 
such as salmon or anchovies. Also, they could not have recurrent digestive problems, convulsion 
disorder, autoimmune or inflammatory diseases, and they could not take any pain, allergy, or 
recreational drugs within two days prior to the experiment. They could not have acute illness on 
the day of the experiment or have consumed alcohol within the previous twelve hours. Caffeine 
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consumption within four hours of the study and regular or recent use of non-steroidal anti-
inflammatories also excluded participants. The exclusion criteria are justified to avoid variability 
and to collect data on overall healthy individuals that do not regularly ingest supplements that 
could have similar effects as the study supplement, curcumin, and that do not take medications 
that could have an effect on their pain response. In addition, much of the exclusion criteria 
involved chronic illness, pain, or obesity in order to exclude participants with possible high 
amounts of inflammation that could also influence data as curcumin is an anti-oxidant and anti-
inflammatory. 
 
Among the 21 subjects, 2 were unable to participate due to their ineligibility upon arrival to the 
laboratory; 2 participants did not show up to either the first or second visit.  Furthermore, some 
analyses may include fewer than seventeen subjects as a result of equipment failure, but they will 
be labeled as such. Participants were 17 college students with a mean age of 19.06 years (SD= 
.66), and 82% were female (see Table 1 for demographics).  The mean BMI of the participants 
was 22.35 (SD=2.46) ranging from 18 to 28.  
 
Table 1: Demographics 
Demographics N = 17 
Males 3 
Females 14 
Right handed 17 
Caucasian  14 
Asian 2 
Latin American 1 
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2.2 Apparatus and Physiological Recording 
Participants were tested in a sound proof room. Blood pressure was collected after questionnaires 
at the beginning of the experiment using Biopac MP150 equipment (Biopac Systems Inc. Goleta, 
California). Skin temperature and room temperature were periodically measured to account for 
major changes. 
 
2.3 Self-Report Data 
Participants answered questionnaires during both visits in order to assess psychological states, 
perception of pain, and general health status. Questionnaires were presented via Qualtrics Survey 
Software and LabView.  
 
2.3.1 Center for Epidemiologic Studies Depression Scale The	  Center	  for	  Epidemiologic	  Studies	  Depression	  Scale	  -­‐	  CESD	  (Appendix	  A)	  was	  used	  during	  both	  lab	  visits	  as	  it	  measures	  trait	  depression	  and	  anxiety	  characteristics	  within	  the	  previous	  week,	  which	  has	  been	  shown	  to	  alter	  one’s	  pain	  state	  (Radloff,	  L.S.,	  1991;	  Rhudy	  and	  Meagher,	  2000).	  	  	  
2.3.2 The Depression Anxiety Stress Scale The	  Depression	  Anxiety	  Stress	  Scale	  –	  DASS	  (Appendix	  A)	  was	  used	  during	  both	  lab	  visits	  because	  it	  evaluates	  one’s	  current	  depression	  and	  anxiety	  state,	  which	  can	  play	  a	  role	  in	  one’s	  pain	  state (Lovibond, P. F., and Lovibond, S. H., 1995; Rhudy	  and	  Meagher,	  2000).	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2.4 Self Assessment Manikin (SAM) 
The Self Assessment Manikin was used throughout both visits of the study to measure 
psychophysical experience of pain as it evaluates pleasure, arousal, and dominance, which assists 
in understanding the subject’s perception of pain intensity and unpleasantness across various 
stimuli (Bradley and Lang, 1994). Higher ratings of valence correspond to a more positive mood 
with a lower rating associated with a negative mood. Similarly, a higher rating in arousal 
corresponds to a more physiologically aroused state, and a higher numerical rating in dominance 
indicates a greater sense of control of the situation. The subjects underwent SAM training during 
the both visits, and SAM was completed before, after, and during pain testing throughout both 
visits.  
 
2.5 Capsaicin 
Each visit involved the application of 1 milliliter of Zostrix capsaicin lotion with a .075% 
concentration. It was applied to the non-dominant volar forearm for thirty minutes following five 
minutes of heat stimulation using the Medoc Advance Thermal Stimulator (Medoc Ltd. Ramat 
Yishai, Israel). Capsaicin was used to induce a flare response, spontaneous pain and primary 
hyperalgesia. The Capsaicin used in this experiment is the active ingredient found in peppers like 
jalapenos and habanero peppers. It is a naturally derived ingredient that is safe for consumption. 
Capsaicin is also used in over-the-counter products and creams used to treat pain and muscle 
soreness, including brand names such as Capsin or Zostrix. Capsaicin has been used for years as 
a standardized method in studies to mimic aspects of pain analogous to chronic pain conditions; 
it has been used extensively in behavioral and psychological studies. 
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2.6 Curcumin  
This study is predominantly evaluating the anti-hyperalgesic effects of curcumin, also known as 
turmeric, which is an herb used in food spices and herbal medicine with therapeutic effects due 
to its anti-inflammatory and anti-oxidative nature (Arora et al., 1997; Kandhare et al., 2012; 
Singh, 2007). Curcumin is available over-the counter, inexpensive, safe in high doses even at 12 
grams a day in humans, and is declared as “generally regarded as safe (GRAS)” by the United 
States FDA (Cheng et al., 2001; Lao et al., 2006; Moreaux et al, 2004). Curcumin capsules (1000 
mg each) used in the study were provided by Sabinsa Corporation (Curcumin C3 Complex ®, 
Sabinsa Corporation Payson, UT). Participants were informed that they may receive a placebo or 
natural supplement in a double-blind process so that neither the experimenter nor the participant 
would be aware of the material assigned. Furthermore, participants were given instructions to 
take two tablets every evening and morning between 8 and 10 PM and 8 and 10 AM every day 
including the day of the first visit. Subjects were instructed to respond to reminder texts with a 
“y” after each time prompted to take the supplement once it was consumed. Reminder texts were 
scheduled using Google Voice and an SMS scheduling extension provided by Google Chrome. 
All contact information was stored in a secure place that only the co-investigators had access to.  
 
 
2.7 Pain Ratings  
Participants used a visual analog scale (VAS) presented on the computer using LabView version 
8.0 software (National Instruments, Austin, TX) to make ratings of pain intensity and 
unpleasantness throughout the experiment. The scale ranges from 0 to 10 with verbal descriptors 
as anchors beginning with 0 (no pain) to 10 (most intense pain imaginable) and 0 (not at all 
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unpleasant) to 10 (most unpleasantness imaginable).  This scale was used during von Frey 
training, long thermal stimulation, capsaicin application, and testing for secondary hyperalgesia. 
 
2.8 Von Frey Testing  
Von Frey filaments were used to assess secondary hyperalgesia. These filaments are composed 
of flexible nylon and are organized according to thickness. As they increase in thickness and 
gram units as indicated on each brush, the pressure of their application increases. The von Frey 
must be held perpendicular to the target, and it is pressed onto the skin until it bends. We used a 
26 gram filament immediately after the flare image is taken after the thirty minutes of capsaicin. 
The covering and capsaicin lotion were gently removed without rubbing the lotion into the skin 
more or spreading it outside of the site, and the von Frey was pressed onto each spoke of each 
radian of the grid beginning from the outside and moving inward. Each participant also was 
trained to make ratings with the von Frey during the first visit, during which only two radians 
were drawn onto the dominant arm, and two different von Frey sized filaments (26g, and 300g) 
were applied to the arm for each participant.  Subjects rated the pain intensity for each spoke on 
the VAS, and were instructed to differentiate between pain and pressure.  
 
 
2.9 Thermal Threshold Pain Testing 
Participants underwent assessment of thermal pain thresholds using Medoc Advance Thermal 
Stimulator (Medoc Ltd. Ramat Yishai, Israel). They were asked to place the thenar eminence of 
the non-dominant hand on a three by three centimeter thermode. The warm thermode began at 35 
degrees Celsius and increased at a rate of 0.5 degrees Celsius per second until participants 
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clicked a mouse at the first sensation of pain. The thermode had a cutoff temperature of 51 
degrees in order to prevent injury. This procedure was described during informed consent, and 
instructions were given beforehand.  Each participant had one practice trial, and three additional 
trials from which the average was taken to determine his or her pain threshold. Furthermore, 
participants repeated this method after capsaicin application during which threshold was 
determined on the application site immediately following von Frey testing. The thermode was 
covered with plastic wrap, and it was placed onto the site for four trials.  
 
2.10 Heat-Capsaicin Application 
To begin spontaneous pain testing with capsaicin application, participants placed a warm 
thermode (Medoc Ltd. Ramat Yishai, Israel) onto the application site, which was heated at forty-
five degrees Celsius for five minutes to prime the area. This served as a long thermal stimulation 
test (LTS) as the participant rated his or her pain intensity every minute on the VAS. 
Immediately after the five minutes, the capsaicin solution was applied and covered for thirty 
minutes during which the participant made spontaneous pain intensity and unpleasantness ratings 
every three minutes along with SAM. This heat-capsaicin method has been used many times in 
previous studies, and it is utilized to initiate stable cutaneous sensitization resulting from the heat 
and cream so that we may use a lesser solution (Dirks et al., 2003; Petersen et al., 2001; Petersen 
and Rowbotham, 1999). 
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2.11 Data Analysis 
Paired t-tests were used to compare within groups between visit 1 and visit 2 for measures 
involving two variables. Repeated measures ANOVAs were performed in order to compare 
within group effects on multiple variables.  
 
2.11.1 Handling Missing Data Values 
Some values were missing due to equipment failure throughout the tests. As a result, the group 
means were utilized to replace any missing values that occurred during the suprathreshold pain 5 
minutes of 45° heat, thirty minutes of capsaicin-induced spontaneous pain, and von Frey 
secondary hyperalgesia mapping.  
  
2.12 Procedure 
Participants entered the laboratory and were instructed to take off jewelry on their wrists and 
fingers. They washed their hands and forearms, and eligibility criteria were checked again to 
ensure no recent ingestion of antihistamines, caffeine, alcohol, pain medicine or recreational 
drugs as well as no acute illness that day. Body Mass Index (BMI) was also assessed using an 
electronic scale and measuring tape attached to the wall. Participants then sat down in the testing 
room, listened to an audio track, and read a physical copy of the informed consent. Subjects then 
filled out questionnaires presented via Qualtrics Survey Software, which are listed in section 2.3. 
The subjects were then prompted to undergo SAM training and SAM baseline was assessed 
thereafter as described in section 2.4. After questionnaires, blood pressure measures were taken; 
if blood pressure were abnormal, the subjects were ineligible to continue with the study.   
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The participants were then instructed how to indicate thermal pain thresholds explained in 
section 2.9, and they participated in four heat- threshold trials. They were then given instructions 
on how to rate their pain using the VAS, and they were asked to recall the last time they cut their 
finger and to rate the intensity and unpleasantness of that experience on the VAS to ensure the 
instructions were understood. Next, the von Frey map was drawn in its entirety on the non-
dominant arm with a washable marker during both visits. The first visit also included a grid with 
only two radians drawn on the dominant arm for training described in section 2.8. Skin 
temperature and room temperature were collected before the five minutes of heat began on the 
non-dominant volar forearm. During the five minutes of steady heat, participants made SAM and 
spontaneous pain ratings on the VAS each minute.  
 
Measurements of skin temperature were then collected again before applying capsaicin lotion to 
the application site. The subjects were instructed to make VAS ratings of pain intensity and 
unpleasantness every three minutes as prompted by the computer. The experimenter left the 
room after the participant made the first rating and instructions were understood. They were 
monitored via a web-camera in the room, of which they were informed. Subjects could also 
contact the experimenter using a walkie-talkie left in the room with them. After the thirty 
minutes of capsaicin, the covering was removed. Skin temperature and room temperature were 
measured, and a flare image of blood flow was taken using a moorLDI2 Laser Doppler Imager 
(MoorLDI2-IR, Moor Instruments, Devon, United Kingdom). Von Frey testing for area of 
secondary hyperalgesia took place immediately after the flare image (section 2.8). Thereafter, 
participants underwent thermal thresholds utilizing the Medoc once again; however, this time 
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applied to the application site. To prevent capsaicin residue from getting onto the thermode, a 
plastic wrap was wrapped around it before being placed onto the forearm (section 2.9).  
 
Finally, all of the remaining capsaicin lotion was removed with vegetable oil, and the 
participants thoroughly washed their forearm. The area of application was covered in case of any 
remaining lotion. During the first visit, participants were given their supplement along with 
instructions for the next seven days, which is described in section 2.6. At the second visit, after 
curcumin consumption, participants went through the same procedures as the first visit except for 
the von Frey training.  
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CHAPTER III 
RESULTS 
3.1 Psychological Characteristics 
The CES-D and DASS self-report questionnaires were administered at the beginning of each 
visit to evaluate depression for the former and depression, stress, and anxiety for the latter. 
Participants did not significantly differ between visits in their perceived stress (t (14) = .68, p = 
.50), anxiety scores (t (14)= .70, p = .50), or depression scores (t (14)= .57, p = .58) in the DASS. 
Furthermore, the groups did not differ in depression scores evaluated by the CES-D (t (15) = .62, p 
= .55).  
 
3.2 Heat Pain Detection Thresholds 
Paired t-tests were used to compare heat pain detection thresholds before and after curcumin 
consumption. There was no significant difference between visit 1 (M = 43, SEM = .55) and visit 
2 (M = 43, SEM = .49), (t (16) = .87, p = .40), as seen in Figure 1.  
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Figure 1: Comparison of heat pain detection thresholds of which there is no significant 
difference p > .1. 
 
3.3 Suprathreshold Spontaneous Pain Ratings  
A two-way repeated measures ANOVA revealed a significant difference between the baseline 
suprathreshold pain intensity ratings and post-curcumin ratings F (1,32) = 11.80, p < .01, which 
can be seen in Figure 2. There was also a significant effect of time, F (4,256) = 2.97 p < .05; 
however, there was no significant interaction of time and visit p = .76. Similarly, a two-way 
repeated measures ANOVA showed a significant effect of visit on unpleasantness ratings using 
the VAS during the 5 minutes of heat (Figure 3), F(1,32) = 8.78, p < .01; however, there was no 
effect of time p = .22, nor was there an interaction of time and visit  p = .67. 
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Figure 2: Suprathreshold spontaneous pain intensity ratings over 5 minute period of 45° Celsius 
heat between the baseline visit 1 and visit 2 after consuming curcumin for 7 days p < .01. 
Ratings were made on a Visual Analog Scale.  
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Figure 3: Suprathreshold spontaneous pain unpleasantness ratings over 5 minute period of 45° 
Celsius heat between the baseline visit 1 and visit 2 after consuming curcumin for 7 days p < .01. 
Ratings were made on a Visual Analog Scale. 
 
3.4 Affective Response to Pain 
A two-way repeated measures ANOVA found that there was a marked difference in valence 
between the two visits, F (1,80) = 88.10, p < .01, seen in Figure 4. There was not a significant 
effect of time p = .81, nor was there an interaction effect p = .64. Based on the results of another 
two-way repeated measures ANOVA, there was also a significant effect of visit on arousal 
(Figure 5), F (1,80)= 38.98, p < .01, but there was no main effect of time p = .90, nor was there an 
interaction p = .60. Finally, a two-way repeated measures ANOVA found a significant effect of 
visit on dominance, F (1,80)= 36.90, p < .01, see Figure 5, but it did not find a marked effect of 
time  p = .91. There was also no significant interaction of time and visit p = .48. 
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Figure 4: SAM ratings of valence before and after curcumin consumption. Higher ratings 
correspond with decreased negative affect,  p < .01. Ratings were made each minute for five 
minutes of 45° Celsius heat.  
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Figure 5: SAM ratings of arousal after curcumin consumption, which significantly differed, p < 
.01. Higher ratings correspond with increased arousal. Ratings were made each minute for five 
minutes of 45° Celsius heat. 
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Figure 6: SAM ratings of dominance before and after curcumin consumption, which 
significantly differed as ratings of dominance increased during the second visit indicating a 
greater sense of control,  p < .01. Ratings were made each minute for five minutes of 45° Celsius 
heat. 
 
3.5 Capsaicin-Induced Spontaneous Pain Ratings 
A two-way repeated measures ANOVA revealed a significant effect of visit on spontaneous pain 
intensity ratings made by participants every three minutes during the thirty minutes of capsaicin 
application following a five minute heat stimulus, F (9,288) = 17.34, p < .01. Ratings were 
significantly decreased during the second visit compared to the first visit, see Figure 7. 
Furthermore, there was no significant effect of time,  p = .09, nor was there an interaction of time 
and visit p = .25. In addition, a two-way repeated measures ANOVA showed a significant effect 
of visit on spontaneous unpleasantness ratings, F (9,288) = 20.88, p < .01, such that ratings were 
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significantly decreased after curcumin consumption, see Figure 8. There was not a significant 
effect of time p = .17, nor was there a marked interaction between visit and time, p = .15. 
 
 
 
Figure 7: Pain intensity ratings on a VAS during the thirty minutes of capsaicin application, p < 
.01. Ratings were made every three minutes. 
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Figure 8 Unpleasantness ratings on a VAS during the thirty minutes of capsaicin application, p < 
.01. 
 
3.6 Area of Secondary Hyperalgesia 
A paired t-test found no significant difference between the area of secondary hyperalgesia during 
the first baseline visit, M = 45 cm2, SEM = 9.8 cm2, and the second visit after curcumin 
intervention, M = 55 cm2, SEM = 11 cm2, ( t (16) = 1.3,  p = .21), as seen in Figure 9. 
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Figure 9: Area of secondary hyperalgesia from von Frey mapping, p = .21. 
 
3.7 Neurogenic Inflammation 
After performing a paired t-test, no significant difference in flare was observed between the first 
visit, M = 44, SEM = 3.5, and the second visit after curcumin consumption,  M = 41, SEM = 3.9, 
(t (16) = 1.3,  p = .22), as seen in Figure 10.  
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Figure 10: Comparison of flare area observed between visit 1 and visit 2, p = .22. 
 
3.8 Adherence to Supplement Assignment 
Participants were asked to return their remaining supplement tablets upon the second laboratory 
visit of the study. 15 participants out of 17 brought back their remaining tablets or empty 
containers, and their percentage of assigned supplement consumed based on this method is 
illustrated in Figure 11, M = 84.52%, SD = 18.29. 
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Figure 11: Percent of consumed supplement for the 15 participants that returned their containers.  
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CHAPTER IV 
DISCUSSION 
The purpose of this study was to test the potential anti-hyperalgesic effects of a curcumin 
supplement on pain processes within a healthy population. Results provide preliminary support 
for several of our initial hypotheses. As expected, curcumin significantly reduced pain intensity 
and unpleasantness ratings during suprathreshold thermal stimulation at 45 degrees Celsius, a 
pain stimulus that activates C-fibers, but it had no effect on threshold stimulation that activates 
A- delta fibers. Furthermore, we observed a marked effect of curcumin on capsaicin-induced 
thermal hyperalgesia, which was reflected by reduced pain intensity and unpleasantness ratings 
during the thirty- minute capsaicin application period. Capsaicin-induced pain mimics many of 
the symptoms of neuropathic pain and engages many of the same underlying mechanisms. 
Specifically, it also activates C-fibers via the transient receptor potential vanilloid 1 (TRPV1) 
receptor and elicits a similar burning and tingling effect experienced in those with chronic pain. 
Curcumin’s antihyperalgesic effect on capsaicin-induced neurogenic pain is in line with previous 
animal studies our methods emulated (Yeon et al., 2010). Thus, the effects observed in prior 
animal studies appear to generalize to humans.  
 
Furthermore, our participants reported a significant decrease in negative affect and arousal as 
well as an increase in dominance or locus of control during the suprathreshold pain test. This is 
interesting but not surprising, as other studies have found similar effects of curcumin on mood 
due to its nature to downregulate inflammatory cytokines (Anand et al., 2008; Kulkarni, et al., 
2009). The mood elevating effects of curcumin have been attributed to its ability to downregulate 
proinflammatory cytokines. Reduced negative affect and arousal could also be related to reduced 
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pain sensitivity since Strand et al. (2007) found that arthritis patients reported minimized pain 
during weeks they also reported more positive affect. Further investigation could provide insight 
into the relative contribution of curcumin on the relationship between affect and pain.  
 
Although we did not observe an effect of curcumin on area of secondary hyperalgesia and 
neurogenic inflammation (flare), there was a slight trend of decreased flare between visits. The 
unexpected lack of robust findings in neurogenic inflammation thus far is possibly due to the 
small sample size or to individual differences in stressful life events or adherence to the 
curcumin regimen. These factors may have also contributed to the negative effect on secondary 
hyperalgesia. Alternatively, the area of secondary hyperalgesia may not be as sensitive a measure 
as mechanical allodynia previously used in animal studies of curcumin’s effects on neuropathic 
pain (Jeon et al., 2013). To evaluate this possibility, future studies will incorporate measures of 
mechanical allodynia and hyperalgesia.   
 
Spontaneous pain and primary hyperalgesia observed in response to heat stimulation at the 
application site reflects the sensitization of the primary afferent nociceptors, which in turn 
contribute to the process of central sensitization of spinal cord dorsal horn neurons and pain 
pathways in the brain. In contrast, secondary hyperalgesia in response to mechanical stimulation 
in the area surrounding capsaicin application reflects the underlying process of central 
sensitization. Because most clinical pain syndromes involve both peripheral and central 
sensitization during the development of chronic pain, the anti-hyperalgesic effects of curcumin 
on the capsaicin pain test in healthy humans are likely to predict the therapeutic effects on 
clinical pain. 
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There were no significant differences in heat pain thresholds before or after capsaicin 
application, which is counter to our hypothesis because the post-capsaicin thresholds are also a 
measure of thermal primary hyperalgesia, which animal studies have seen a difference in the tail-
withdrawal test after sensitization from reserpine injection (Arora, et al., 2011). However, the 
lack of difference in thresholds is in line with a separate study’s evaluation of rats that showed 
no effect of curcumin on withdrawal response latencies without capsaicin (Yeon, et al., 2010). 
Yeon has shown that curcumin acts by antagonizing TRPV1 receptors. TRPV1 receptors are 
activated by temperatures greater than 43 °C (109 °F) and by capsaicin. Whether an effect of 
curcumin on heat pain threshold is observed or not may depend on the heat stimulus ramp speed 
and peak heating temperature of the skin. A rapid ramp speed and high peak temperature may 
allow the heat stimulus to activate TRPV1 receptors before eliciting a reflexive withdrawal 
response (e.g., Arora et al. 2011). Moreover, other evidence suggests that the occurrence of 
visual or auditory cues predicting the onset of the heat stimulus may allow subjects to make an 
avoidance responses to the heat before it has reached pain threshold (King et al. 1997), prior to 
the activation of TRPV1 receptors (e.g., Yeon et al 2010). Because cues are readily available in 
Medoc threshold testing in human subjects, it may have allowed subjects to make avoidance 
responses thereby preventing TRPVI activation. To resolve this issue, future studies will need to 
examine whether increasing stimulus ramp speed during threshold testing and shielding subjects 
from cues of heat onset yield a different pattern of results. 
 
Important limitations to consider in this study are, as stated before, the mental and physical 
health of our sample. Age, health conditions, chronic pain, BMI, and diet were all considered in 
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this study resulting in a healthy set of individuals with low inflammatory tone. The small sample 
size is also a limitation with a study that involves many measures and the possible variability due 
to the stress of testing and pre-existing individual differences. Because the participants were 
college students, their lives fluctuated in regard to stress as a result of tests, sleep, and diet, 
which can introduce individual variation that is not present in animal studies where one can 
easily control the environmental histories and genetic backgrounds of the subjects. Another 
limitation was ensuring that the college students receiving credits for their psychology course 
were taking their supplements. They were sent reminder texts, given instructions verbally and on 
paper, and asked to bring their remaining tablets back, but it is still difficult to be certain of 
accountability. In addition, although our results are significant, we hope that the findings will be 
more robust after future incorporation of a placebo comparison group. By administering both 
placebo and curcumin to separate groups, we will be able to compare within and between groups 
to eliminate the possibility of an effect of experience in the laboratory on pain perception 
differences. 
 
To our knowledge, this is the first study evaluating curcumin’s anti-hyperalgesic potential on 
humans in a laboratory setting. After acquiring more data from a larger sample size, we will 
examine whether the amount of supplement consumed may correspond to the resulting pain 
experience in a dose-dependent manner. Furthermore, these findings support the concept that 
pain and neurogenic inflammation are regulated by many independent processes, and it brings 
forth, even more so, the need for continued pain-related research. Should curcumin continue to 
induce significant effects on laboratory pain in healthy subjects, the next step will be to 
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investigate curcumin’s effects in a clinical population with chronic pain and neurogenic 
inflammation.  
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